uniQure to pay APHB up to $4.9 in milestones, $100k annual fee, low single digital % net sales Royalties, FDA filing
Excerpt from uniQure's IPO SEC filing. APHB royalty stream to commence in first half of 2014 in EU. Also great new, they'll file an Investigational New Drug application, or IND, with the FDA for Glybera in the first half of 2014
We have to date paid to AmpliPhi a one-time up-front payment of $1,750,000. We have agreed to pay AmpliPhi annual fees of $100,000, a total of $4,950,000 in development and regulatory milestone payments, and a royalty equal to a low single-digit percentage of net sales, if any, of licensed products sold by us or Chiesi.
We met with the Food and Drug Administration, or FDA, to discuss the regulatory pathway for Glybera in the United States, We plan to file an Investigational New Drug application, or IND, with the FDA for Glybera in the first half of 2014. |